He has experience in all phases of drug development across several therapeutic areas. His core expertise is in the field of CNS drug development, development of ATMPs, exploratory clinical development and Clinical Pharmacology. He leads a group of clinical program leaders within BI’s Innovation Unit responsible for clinical aspects of developing new treatment modalities like ATMPs and indications beyond BI’s established core indications. He is board certified in Clinical Pharmacology, board certified in Anaesthesiology and Intensive Care, holds a Diploma of the European Society of Anaesthesiology and is an authorized Physician for speciality training in Clinical Pharmacology (Chamber of Physicians, German Medical Association).